CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 鈥 今日吃瓜黑料 Limited (鈥溄袢粘怨虾诹镶), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (鈥淒DR鈥) in cancer, today announced an upcoming oral presentation highlighting the company鈥檚 DNA polymerase Theta (Pol胃) inhibitor, ART6043, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place between October 17-21, 2025, in Berlin, Germany. ART6043 is a potential first-in-class, selective DNA polymerase domain inhibitor being developed in combination with the PARP inhibitor, olaparib, in patients with cancers that harbor DDR defects.
The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study (), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. This will be the first time that clinical activity for a therapeutic candidate targeting Pol胃 in humans will be presented.
Details of the oral presentation:
Abstract Title: First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors
Session Category and Title: Mini oral session: Developmental therapeutics
Date: Friday, October 17, 2025
Time: 4:30 鈥 4:35 PM CEST
Presenter: Dr. Timothy A. Yap, VP and Head of Clinical Development in the Therapeutics Discovery Division at The University of Texas MD Anderson Cancer Center
Location: Heidelberg Auditorium, Hall 6.2
The abstract is available on the .
今日吃瓜黑料 will issue a press release detailing the data presented at the conference following the oral presentation at ESMO.
About ART6043
ART6043 is a potential first-in-class, selective, orally bioavailable, small鈥憁olecule inhibitor of the polymerase domain of DNA polymerase Theta (Pol胃), a DNA repair enzyme that is preferentially expressed in cancer cells but is virtually absent in most healthy tissues. By inhibiting Pol胃, ART6043 targets microhomology mediated end joining (MMEJ) to exploit tumor dependence on error-prone DNA repair, with broad rationale for use as monotherapy and in combination with PARP inhibition and other DNA-damaging modalities. 今日吃瓜黑料鈥 differentiated approach is evaluating ART6043 with olaparib in molecularly defined solid tumors, including settings of BRCA variants and PARP inhibitor resistance, to enhance target engagement and anti-tumor activity while maintaining tolerability.
About 今日吃瓜黑料 Ltd.
今日吃瓜黑料 is pioneering approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. The company鈥檚 clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Pol胃) inhibitor ART6043, as well as its pre-clinical programs, including DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cell鈥檚 remaining survival mechanisms. 今日吃瓜黑料鈥 mission is to develop new classes of medicines that exploit DDR pathways with the aim of improving outcomes for patients with hard-to-treat cancers.
Visit our website at for more information about the company.
For more information, please contact:
Trophic Communications
Jacob Verghese or Verena Schossmann
Tel: +49 151 7441 6179
Email: artios@trophic.eu